Corbus Pharmaceuticals (CRBP) Proxy filing summary

Executive summary

• Supplement details amended and restated employment agreements for CEO Yuval Cohen and CFO Sean Moran, effective April 15, 2026, and expiring April 15, 2028.

• All other information in the original proxy statement and proxy card remains unchanged.

Executive compensation and say-on-pay

• CEO Yuval Cohen's new agreement sets an annual base salary of $673,625 for a two-year term, with other terms unchanged from the prior agreement.

• CFO Sean Moran's new agreement sets an annual base salary of $501,273 for a two-year term, with other terms unchanged from the prior agreement.

Voting matters and shareholder proposals

• Shareholders are encouraged to vote using the existing proxy card; prior votes remain valid and do not require resubmission.